Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates

This publication has 54 references indexed in Scilit:

• A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome
  Nature Genetics, 2013
• Gene Therapy for Aromatic l -Amino Acid Decarboxylase Deficiency
  Science Translational Medicine, 2012
• Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins
  Molecular Therapy, 2011
• MECP2 Isoform-Specific Vectors with Regulated Expression for Rett Syndrome Gene Therapy
  PLOS ONE, 2009
• Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome
  Annals of Neurology, 2009
• Reversal of Neurological Defects in a Mouse Model of Rett Syndrome
  Science, 2007
• Duplication of the MECP2 Region Is a Frequent Cause of Severe Mental Retardation and Progressive Neurological Symptoms in Males
  The American Journal of Human Genetics, 2005
• Mild overexpression of MeCP2 causes a progressive neurological disorder in mice
  Human Molecular Genetics, 2004
• Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
  Journal of Virology, 2004
• Rett's Syndrome: Prevalence and Impact on Progressive Severe Mental Retardation in Girls
  Acta Paediatrica, 1985